Literature DB >> 11096753

Depression in Parkinson's Disease.

.   

Abstract

Depression is very common in Parkinson's disease (PD), but its severity and particular symptoms vary. It can often be difficult to diagnose because many of the symptoms typically associated with depression (eg, sleep difficulties, fatigue) can be seen in nondepressed patients with PD, and signs thought to represent depression (eg, lack of facial expression, slowness) can be produced by PD itself. Apathy, although a possible feature of depression, can exist apart from depression and is often associated with cognitive impairment. Therefore, when evaluating patients with PD for possible depression, one should concentrate on the psychological or ideational aspects of the illness. One must determine whether the patient feels sad or hopeless or has a marked inability to enjoy life. Once it has been determined that the patient has clinically significant depressive symptoms, it is important to let him or her know that depression is an aspect of PD requiring treatment, just like the motor manifestations of the disease. The idea of adding antidepressant medications and the possibility of psychotherapy should be introduced. A very reasonable first-choice antidepressant is either sertraline or paroxetine. Because of isolated case reports of worsening motor function associated with institution of a selective serotonin reuptake inhibitor (SSRI), one should keep track of when the medication was started so that the patient can be seen again within a month. It is important from a psychological perspective to have regular follow-up visits when treating depression. If the SSRIs are ineffective or not tolerated, nortriptyline is a good next choice. It has fewer anticholinergic effects and is less likely to cause or worsen orthostatic hypotension than other tricyclic antidepressants. Amitriptyline, although an old favorite of neurologists, is very sedating and has too much anticholinergic activity to be well tolerated in the higher doses needed to treat depression. If a patient could benefit from a dopamine agonist from a motor standpoint and his or her depressive symptoms are mild, consider using pramipexole, which may improve mood and motivation (although this has not yet been proven in a well-controlled trial). It is a good idea to keep patients on antidepressant therapy at least 6 months; many patients require long-term treatment. If a patient is severely depressed, he or she should be referred to a psychiatrist, who may consider admission to the hospital and possible electroconvulsive therapy.

Entities:  

Year:  2000        PMID: 11096753     DOI: 10.1007/s11940-000-0008-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  40 in total

1.  Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series.

Authors:  I H Richard; A Maughn; R Kurlan
Journal:  Mov Disord       Date:  1999-01       Impact factor: 10.338

2.  Moclobemide and selegeline in the treatment of depression in Parkinson's disease.

Authors:  E N Steur; L A Ballering
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 3.  Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century.

Authors:  M S George; E M Wassermann; R M Post
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1996       Impact factor: 2.198

4.  Fluoxetine and extrapyramidal side effects.

Authors: 
Journal:  Am J Psychiatry       Date:  1989-10       Impact factor: 18.112

5.  Desipramine in treatment of Parkinson's disease. A placebo-controlled study.

Authors:  L Laitinen
Journal:  Acta Neurol Scand       Date:  1969       Impact factor: 3.209

6.  Maintenance electroconvulsive therapy for Parkinson's disease.

Authors:  D Aarsland; J P Larsen; O Waage; J H Langeveld
Journal:  Convuls Ther       Date:  1997-12

7.  A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group.

Authors:  I H Richard; R Kurlan
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

8.  Treatment of depression in Parkinson's disease: a meta-analysis.

Authors:  T Klaassen; F R Verhey; G H Sneijders; N Rozendaal; H C de Vet; H M van Praag
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1995       Impact factor: 2.198

9.  Does fluoxetine exacerbate Parkinson's disease?

Authors:  C F Caley; J H Friedman
Journal:  J Clin Psychiatry       Date:  1992-08       Impact factor: 4.384

10.  Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.

Authors:  A Illi; S Sundberg; P Ojala-Karlsson; M Scheinin; A Gordin
Journal:  Clin Pharmacol Ther       Date:  1996-04       Impact factor: 6.875

View more
  5 in total

Review 1.  Transcranial magnetic stimulation for the treatment of depression in neurologic disorders.

Authors:  Felipe Fregni; Alvaro Pascual-Leone
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 2.  Depressive symptoms in neurodegenerative diseases.

Authors:  Miquel Baquero; Nuria Martín
Journal:  World J Clin Cases       Date:  2015-08-16       Impact factor: 1.337

3.  Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.

Authors:  Sonja Krösser; Roland Neugebauer; Hugues Dolgos; Markus Fluck; Karl-Ludwig Rost; Andreas Kovar
Journal:  Eur J Clin Pharmacol       Date:  2006-03-07       Impact factor: 2.953

4.  Sertraline in the treatment of depressive disorders in patients with Parkinson's disease.

Authors:  Silvia Marino; Edoardo Sessa; Giuseppe Di Lorenzo; Giuseppina Digangi; Antonella Alagna; Placido Bramanti; Paolo Di Bella
Journal:  Neurol Sci       Date:  2008-11-11       Impact factor: 3.307

5.  Desipramine protects neuronal cell death and induces heme oxygenase-1 expression in Mes23.5 dopaminergic neurons.

Authors:  Hsiao-Yun Lin; Wei-Lan Yeh; Bor-Ren Huang; Chingju Lin; Chih-Ho Lai; Ho Lin; Dah-Yuu Lu
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.